Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 31422062 · doi:10.1016/S2213-8587(19)30249-9
What was done
Authors conducted a systematic review and random-effects meta-analysis of MEDLINE and the Cochrane Central Register of Controlled Trials through June 15, 2019. They evaluated placebo-controlled cardiovascular outcome trials of GLP-1 receptor agonists in patients with type 2 diabetes reporting major adverse cardiovascular events (MACE: cardiovascular death, stroke, or myocardial infarction). Outcomes included MACE, MACE components, all-cause mortality, heart failure hospitalization, composite kidney outcomes, and safety endpoints (severe hypoglycemia, pancreatitis, pancreatic cancer), alongside subgroup analyses across clinical and drug characteristics.
What was found
Seven trials comprising 56,004 participants were included (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, and PIONEER 6). GLP-1 receptor agonists significantly reduced: - MACE by 12% (HR 0.88, 95% CI 0.82–0.94; p<0.0001) without significant subgroup heterogeneity - Cardiovascular mortality (HR 0.88, 95% CI 0.81–0.96; p=0.003) - Fatal or non-fatal stroke (HR 0.84, 95% CI 0.76–0.93; p<0.0001) - Fatal or non-fatal myocardial infarction (HR 0.91, 95% CI 0.84–1.00; p=0.043) - All-cause mortality (HR 0.88, 95% CI 0.83–0.95; p=0.001) - Hospital admission for heart failure (HR 0.91, 95% CI 0.83–0.99; p=0.028) - Broad composite kidney outcome (HR 0.83, 95% CI 0.78–0.89; p<0.0001), primarily driven by reduced urinary albumin excretion No significant increase was found for severe hypoglycemia, pancreatitis, or pancreatic cancer.
Why it matters
This meta-analysis demonstrates that cardiovascular, mortality, and renal risk reductions represent a consistent class benefit of GLP-1 receptor agonists across diverse patient populations with type 2 diabetes.
Limits
The kidney benefit was primarily driven by improvements in urinary albumin excretion rather than hard clinical endpoints like end-stage kidney disease. The analysis relies on study-level summary data across trials with differing agent structures, half-lives, and dosing regimens rather than individual patient-level data.
Cited by
- supports Long-term data on older GLP-1 agonists like liraglutide and exenatide show no increased risk of cancer-related mortality.